Tumor promoting effect of PDLIM2 downregulation involves mitochondrial ROS, oncometabolite accumulations and HIF-1α activation.
Jing-Xing YangYu-Chen ChuangJen-Chih TsengYi-Ling LiuChao-Yang LaiAlan Yueh-Luen LeeChi-Ying F HuangYi-Ren HongTsung-Hsien ChuangPublished in: Journal of experimental & clinical cancer research : CR (2024)
These findings shed light on the complex action of PDLIM2 on mitochondria and HIF-1α activities in lung cancer, emphasizing the role of HIF-1α in the tumor-promoting effect of PDLIM2 downregulation. Additionally, they provide new insights into a strategy for precise targeted treatment by suggesting that HIF-1α inhibitors may serve as therapy for lung cancer patients with PDLIM2 downregulation.